Aurobindo Pharma Q4 PAT falls marginally to Rs. 903 Cr

During the quarter, US formulations revenue increased by 13.5 per cent YoY to Rs. 4,072 crore

Aurobindo receives final ANDA approval for Rivaroxaban Tablets USP, 2.5mg

The product will be launched in Q1FY26

USFDA classifies Aurobindo Pharma Inc's warehouse as OAI

The USFDA has determined the inspection classification status of this warehousing facility as 'Official Action Indicated

Aurobindo Pharma Q2 FY25 net profit up 8.6% at Rs. 817 Cr

Growth markets revenue increased by 44 YoY to Rs. 812 crore

Briefs: Aurobindo Pharma and Lupin

USFDA completes PAI of Lupin’s biotech facility in Pune

Aurobindo Pharma receives USFDA approval for Cephalexin Tablets

The product is expected to be launched in Q3FY25

Aurobindo Pharma to acquire balance 49% stake in GLS Pharma

Briefs: Medicamen Biotech, Aurobindo Pharma and Ajooni Biotech

The sANDA was submitted as “Prior Approval Supplement” for addition of an alternate drug product manufacturing, labeling, packaging, and testing facility

Aurobindo posts Q1 FY25 PAT higher by 61% at Rs. 7,567 Cr

Revenue from Operations increased by 10.5% YoY to Rs. 7,567 crore with growth across the businesses

Aurobindo Pharma receives USFDA approval for Estradiol Vaginal Inserts USP, 10 mcg

The approved product has an estimated market size of US$ 268 million for the twelve months ending June 2024, according to IQVIA